NKGen Biotech (NYSE:NKGN) Shares Down 0.3% – What’s Next?

NKGen Biotech, Inc. (NYSE:NKGN) shares were down 0.3% during mid-day trading on Friday . The company traded as low as $0.50 and last traded at $0.53. Approximately 340,069 shares were traded during trading, a decline of 94% from the average daily volume of 5,615,834 shares. The stock had previously closed at $0.54.

NKGen Biotech Price Performance

The company has a market cap of $23.98 million, a price-to-earnings ratio of -0.11 and a beta of 0.48. The business’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $0.52.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Magnetar Financial LLC acquired a new position in shares of NKGen Biotech in the fourth quarter worth $175,000. Kepos Capital LP acquired a new position in NKGen Biotech in the 4th quarter valued at about $151,000. Polar Asset Management Partners Inc. raised its stake in NKGen Biotech by 9.4% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,181,872 shares of the company’s stock valued at $447,000 after purchasing an additional 101,872 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in NKGen Biotech by 126.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock valued at $102,000 after purchasing an additional 87,000 shares during the last quarter. Finally, Advisory Research Inc. acquired a new position in NKGen Biotech in the 4th quarter valued at about $28,000. 76.17% of the stock is currently owned by institutional investors and hedge funds.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.